Cell biology of Smad2/3 linker region phosphorylation in vascular smooth muscle

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 8, 2012, Pages 661-667

  Rezaei, Hossein B ^a,b   Kamato, Danielle ^a   Ansari, Ghazaleh ^a   Osman, Narin ^a   Little, Peter J ^a  

^a RMIT UNIVERSITY   (Australia)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Phosphorylation; Signalling; Smads; Transforming growth factor ; Vascular smooth muscle

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE; RHO KINASE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL FUNCTION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; OLIGOMERIZATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; GENETIC LINKAGE; HUMANS; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84864317948     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05592.x     Document Type: Review

References (62)

1. Saika S. TGFbeta pathobiology in the eye. Lab. Invest. 2006; 86: 106-15.
2. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-84.
3. Dadlani H, Ballinger ML, Osman N, Getachew R, Little PJ. Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle. J. Biol. Chem. 2008; 283: 7844-52.
4. Massague J. TGF-beta signal transduction. Annu. Rev. Biochem. 1998; 67: 753-91.
5. Ross S, Hill CS. How the Smads regulate transcription. Int. J. Biochem. Cell Biol. 2008; 40: 383-408.
6. Hart PJ, Deep S, Taylor AB, Shu Z, Hinck CS, Hinck AP. Crystal structure of the human TbetaR2 ectodomain-TGF-beta3 complex. Nat. Struct. Biol. 2002; 9: 203-8.
7. Agrotis A, Kalinina N, Bobik A. Transforming growth factor-beta, cell signaling and cardiovascular disorders. Curr. Vasc. Pharmacol. 2005; 3: 55-61.
8. Huse M, Chen YG, Massague J, Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 1999; 96: 425-36.
9. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
10. Meulmeester E, Ten Dijke P. The dynamic roles of TGF-beta in cancer. J. Pathol. 2011; 223: 205-18.
11. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massague J. The TGF beta receptor activation process: An inhibitor- to substrate-binding switch. Mol. Cell 2001; 8: 671-82.
12. Matsuzaki K, Kitano C, Murata M et al. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer. Cancer Res. 2009; 69: 5321-30.
13. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins. Differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J. Cell. Biochem. 2007; 101: 9-33.
14. Guo X, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 2009; 19: 71-88.
15. Hariharan R, Pillai MR. Structure-function relationship of inhibitory Smads: Structural flexibility contributes to functional divergence. Proteins 2008; 71: 1853-62.
16. Shi Y. Structural insights on Smad function in TGFbeta signaling. Bioessays 2001; 23: 223-32.
17. Hill CS. Nucleocytoplasmic shuttling of Smad proteins. Cell Res. 2009; 19: 36-46.
18. Xiao C, Shim JH, Kluppel M et al. Ecsit is required for Bmp signaling and mesoderm formation during mouse embryogenesis. Genes Dev. 2003; 17: 2933-49.
19. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005; 19: 2783-810.
20. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA. Insights on DNA binding in TGF-beta signaling. Cell 1998; 94: 585-94.
21. Yang X, Letterio JJ, Lechleider RJ et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 1999; 18: 1280-91.
22. Yang F, Chung AC, Huang XR, Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways. The role of Smad3. Hypertension 2009; 54: 877-84.
23. Dennler S, Huet S, Gauthier JM. A short amino-acid sequence in MH1 domain is responsible for functional differences between Smad2 and Smad3. Oncogene 1999; 18: 1643-8.
24. Yagi K, Goto D, Hamamoto T, Takenoshita S, Kato M, Miyazono K. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J. Biol. Chem. 1999; 274: 703-9.
25. Wang G, Matsuura I, He D, Liu F. Transforming growth factor-{beta}-inducible phosphorylation of Smad3. J. Biol. Chem. 2009; 284: 9663-73.
26. Burch ML, Zheng W, Little PJ. Smad linker region phosphorylation in the regulation of extracellular matrix synthesis. Cell. Mol. Life Sci. 2011; 68: 97-107.
27. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 1999; 13: 804-16.
28. Burch ML, Yang SN, Ballinger ML, Getachew R, Osman N, Little PJ. TGF-β stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad 2. Cell. Mol. Life Sci. 2010; 67: 2077-90.
29. Chung SW, Miles FL, Sikes RA, Cooper CR, Farach-Carson MC, Ogunnaike BA. Quantitative modeling and analysis of the transforming growth factor beta signaling pathway. Biophys. J. 2009; 96: 1733-50.
30. Wrighton KH, Lin X, Feng XH. Phospho-control of TGF-beta superfamily signaling. Cell Res. 2009; 19: 8-20.
31. Shen X, Hu PP, Liberati NT, Datto MB, Frederick JP, Wang XF. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. Mol. Biol. Cell 1998; 9: 3309-19.
32. Wu S, Xiang K, Zheng T et al. Relationship between the renin-angiotensin system genes and diabetic nephropathy in the Chinese. Chin. Med. J. 2000; 113: 437-41.
33. Wu JW, Hu M, Chai J et al. Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. Mol. Cell 2001; 8: 1277-89.
34. Feng XH, Derynck R. A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity. EMBO J. 1997; 16: 3912-23.
35. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL. TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J. Biol. Chem. 1997; 272: 27678-85.
36. Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGF-beta signal transduction. J. Cell Sci. 2001; 114: 4359-69.
37. Howell M, Itoh F, Pierreux CE et al. Xenopus Smad4beta is the co-Smad component of developmentally regulated transcription factor complexes responsible for induction of early mesodermal genes. Dev. Biol. 1999; 214: 354-69.
38. Correia JJ, Chacko BM, Lam SS, Lin K. Sedimentation studies reveal a direct role of phosphorylation in Smad3. Smad4 homo- and hetero-trimerization. Biochemistry 2001; 40: 1473-82.
39. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 1997; 389: 618-22.
40. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
41. Yoshida K, Matsuzaki K, Mori S et al. Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am. J. Pathol. 2005; 166: 1029-39.
42. Yamaguchi K, Shirakabe K, Shibuya H et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995; 270: 2008-11.
43. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: Implications for carcinogenesis. Oncogene 2005; 24: 5742-50.
44. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J. Cell Sci. 2005; 118: 3573-84.
45. Pera EM, Ikeda A, Eivers E, De Robertis EM. Integration of IGF, FGF, and anti-BMP signals via Smad1 phosphorylation in neural induction. Genes Dev. 2003; 17: 3023-8.
46. Mori S, Matsuzaki K, Yoshida K et al. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 2004; 23: 7416-29.
47. Millet C, Yamashita M, Heller M, Yu LR, Veenstra TD, Zhang YE. A negative feedback control of transforming growth factor-beta signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204. J. Biol. Chem. 2009; 284: 19808-16.
48. Yamagata H, Matsuzaki K, Mori S et al. Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Cancer Res. 2005; 65: 157-65.
49. Wang W, Huang XR, Canlas E et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ. Res. 2006; 98: 1032-9.
50. Li JH, Huang XR, Zhu HJ et al. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: Implications for diabetic renal and vascular disease. FASEB J. 2004; 18: 176-8.
51. Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: From pan inhibition to isoform selectivity. Cell. Mol. Life Sci. 2010; 67: 171-7.
52. Bhowmick NA, Ghiassi M, Aakre M, Brown K, Singh V, Moses HL. TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc. Natl Acad. Sci. USA 2003; 100: 15548-53.
53. Kamaraju AK, Roberts AB. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem. 2005; 280: 1024-36.
54. Chen S, Crawford M, Day RM et al. RhoA modulates Smad signaling during transforming growth factor-beta-induced smooth muscle differentiation. J. Biol. Chem. 2006; 281: 1765-70.
55. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430: 226-31.
56. Alarcon C, Zaromytidou AI, Xi Q et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 2009; 139: 757-69.
57. 2+)-calmodulin-dependent protein kinase II. Mol. Cell. Biol. 2000; 20: 8103-11.
58. Chen CT, Doxsey S. A last-minute rescue of trapped chromatin. Cell 2009; 136: 397-9.
59. Massague J. Integration of Smad and MAPK pathways: A link and a linker revisited. Genes Dev. 2003; 17: 2993-7.
60. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994; 371: 257-61.
61. Lonn P, Moren A, Raja E, Dahl M, Moustakas A. Regulating the stability of TGFbeta receptors and Smads. Cell Res. 2009; 19: 21-35.
62. Gao S, Alarcon C, Sapkota G et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol. Cell 2009; 36: 457-68.